IDEMIA and Kudelski Group Launch Global Partnership to Simplify IoT Connectivity and Security
The Kudelski Group (SIX: KUD.S), the world leader in digital security, and IDEMIA, the global leader in Augmented Identity, today announced a global partnership that provides manufacturers and service providers a single, fully-integrated solution to manage the network connectivity and security of cellular IoT devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190212005047/en/
As more companies of all sizes and sectors create new business models and operational efficiencies by connecting their devices, their success depends on their ability to ensure the security of the devices, data and access to both. Ericsson predicts that approximately 70 percent of all wide-area IoT devices will have cellular connections by 2022.
"In this age of digital transformation, protecting connected devices and the valuable data they generate is critical for the long-term success of the exploding IoT market,” said Jean-Michel Puiatti, Kudelski Group Senior Vice President for IoT Security. “By combining our battle-tested security technologies with IDEMIA’s connectivity solution, we enable companies to deliver secure, connected products to market more quickly.
"Our alliance with the Kudelski Group gives the IoT market a clear signal. We are thrilled to apply our expertise to help bolster IoT security backed by state-of-the-art technology providing for enhanced user trust in everyday devices,” said IDEMIA Executive Vice President for Connected Objects activity Yves Portalier. “This partnership for security is even more essential considering the tremendous potential for connectivity offered by 5G networks.”
The new global partnership integrates IDEMIA’s DAKOTA IoT (eUICC) and TSM (Trusted Service Management) solutions with the Kudelski IoT Security Platform. DAKOTA IoT is a secure hardware and operating system that allows device makers to remotely download mobile operator subscriptions to the connected objects deployed in the field and authorize them to use the network. The Kudelski IoT Security Platform provides device security (firmware lifecycle management), data security (transport- and application-level authentication and encryption), access management (token-based feature activation) and active security (monitoring and AI- based anomaly detection) to device manufacturers. The integration of the two solutions in single device makes sustainable IoT security more widely accessible and decreases the time to market for new IoT solutions.
The integrated platform is fully compliant with GSMA standards and uses Global Platform Alliance recommendations to ensure that security can be updated over the air using standard GSMA mechanisms across all worldwide networks.
About IDEMIA’s DAKOTA IoT eUICC
IDEMIA’s subscription management platform and DAKOTA IoT eUICC provide a turnkey solution allowing mobile operators to remotely allocate subscriptions to connected objects. This comprehensive solution offers the most efficient, secure and transparent technology possible to serve the connectivity needs of mobile operators and to deliver a seamless experience to end-users.
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect, travel and vote), in the physical as well as digital space. Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to $3 billion in revenues and 13,000 employees around the world, IDEMIA serves clients in 180 countries.
Visit IDEMIA at Mobile World Congress, Booth n°6H30.
About the Kudelski IoT Security Platform
The Kudelski IoT Security Platform is part of the Kudelski IoT Security Suite, a comprehensive set of services and solutions designed to make IoT security simple, scalable and sustainable. The platform establishes trust and integrity between devices and their associated applications. It is a universal platform which is tailored to deliver value in vertical-specific ecosystems and is easily integrated into any existing IoT architecture. Learn more about Kudelski IoT solutions and services, visit http://www.kudelski-iot.com or visit us at MWC Barcelona (Hall 2, Executive Meeting Room 2B12Ex). You can request a meeting with us via our website.
About the Kudelski Group
The Kudelski Group (SIX: KUD.S) is a world leader in digital security and a provider of end-to-end convergent media solutions to the digital entertainment industry, including services and applications requiring access control and rights management to secure the revenue in digital television, internet, mobile and interactive applications. The Group also offers cybersecurity solutions and services focused on helping companies assess risks and vulnerabilities and protect their data and systems. It also supplies integrated solutions to manage access control of people and vehicles to sites and events. The Kudelski Group is headquartered in Cheseaux-sur-Lausanne, Switzerland and Phoenix (AZ), USA. For more information, please visit www.nagra.com.
HAVAS PARIS PR AGENCY
+ 33 6 63 73 30 30
Kudelski Group – IoT Security
Head of Marketing
+1 (480) 819-5781
Kudelski Group – Corporate Communications
Senior Manager Media Relations
+41 79 647 61 71
+1 (415) 962-5005
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Abiraterone Acetate Included in World Health Organisation’s Essential Medicines List for the Treatment of Metastatic Castration-Resistant Prostate Cancer19.7.2019 13:05:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson is delighted with the recent announcement from the World Health Organisation (WHO) to include abiraterone acetate (ZYTIGA ® ) for the treatment of metastatic castration-resistant prostate cancer (mCRPC), in the updated Essential Medicines List, published on 9th July 2019.1,2 The WHO’s Essential Medicines List is a core guidance document that helps countries prioritise critical health products that are recommended to be widely available and affordable throughout health systems.1 “The inclusion of abiraterone acetate in the WHO Essential Medicines List highlights the critical role that this treatment can play in improving the lives of patients living with mCRPC and their families,” said Dr. Joaquín Casariego, Janssen Therapeutic Area Lead Oncology for Europe, Middle East & Africa, Janssen-Cilag S.A. “I am proud that we are working hard to impact survival and quality of life by developing and providing innovative medicines which ar
Gilead Sciences Licenses Respiratory and Herpes Antiviral Research Programs From Novartis19.7.2019 12:30:00 CEST | Press release
Gilead Sciences, Inc. (NASDAQ: GILD) announced today that it has licensed three preclinical antiviral programs from Novartis, including investigational agents with the potential to treat human rhinovirus, influenza and herpes viruses. Under the agreement, Gilead will acquire exclusive global rights to develop and commercialize novel small molecules against three undisclosed targets. Novartis will receive an upfront payment and is eligible to receive up to an additional $291 million in potential milestone payments upon achievement of certain development and commercial milestones, as well as royalties on annual net sales. “Today’s announcement builds on Gilead’s heritage in antiviral research and development. We look forward to applying this expertise to advance the development of potential new treatments for viruses with limited therapeutic options,” said John McHutchison AO, MD, Gilead’s Chief Scientific Officer and Head of Research and Development. Gilead’s antiviral portfolio include
Schlumberger Announces Second-Quarter 2019 Results19.7.2019 11:00:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) today reported results for the second quarter of 2019. (Stated in millions, except per share amounts) Three Months Ended Change Jun. 30, 2019 Mar. 31, 2019 Jun. 30, 2018 Sequential Year-on-year Revenue $8,269 $7,879 $8,303 5% 0% Pretax segment operating income $968 $908 $1,094 7% -12% Pretax segment operating margin 11.7% 11.5% 13.2% 17 bps -148 bps Net income - GAAP basis $492 $421 $430 17% 14% Net income, excluding charges & credits* $492 $421 $594 17% -17% Diluted EPS - GAAP basis $0.35 $0.30 $0.31 17% 13% Diluted EPS, excluding charges & credits* $0.35 $0.30 $0.43 17% -19% North America revenue $2,801 $2,738 $3,139 2% -11% International revenue $5,463 $5,037 $5,065 8% 8% North America revenue, excluding Cameron $2,243 $2,178 $2,546 3% -12% International revenue, excluding Cameron $4,761 $4,469 $4,387 7% 9% *These are non-GAAP financial measures. See section titled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commente
Schlumberger Appoints Olivier Le Peuch as CEO19.7.2019 10:46:00 CEST | Press release
Schlumberger Limited (NYSE: SLB) announced today that its Board of Directors has appointed Olivier Le Peuch as its Chief Executive Officer and member of the Schlumberger Board, effective August 1, 2019. Mr. Le Peuch succeeds Paal Kibsgaard, who will retire as Chief Executive Officer effective that same date. Also effective August 1, Mr. Kibsgaard will step down as Chairman of the Board and retire as a member of the Board of Directors. Mr. Kibsgaard will retire after more than 22 years of service to the Company, including eight years as CEO and four years as Chairman. Effective the same date, Mark G. Papa, a current non-independent director, will become non-executive Chairman of the Board. Peter Currie will continue to serve as the Board’s Lead Independent Director. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190719005161/en/ Olivier Le Peuch is appointed Chief Executive Officer and a member of the Schlumberger Board, effe
Fluke Corporation Acquires Industrial Reliability Leader PRÜFTECHNIK19.7.2019 10:00:00 CEST | Press release
Fluke Corp., the global leader in test and measurement instruments, has acquired Ismaning, Germany-based PRÜFTECHNIK, a market leader in precision laser shaft alignment, condition monitoring, and non-destructive testing. “Fluke’s acquisition of PRÜFTECHNIK reflects the growing importance our customers place on reliability systems to keep their equipment in optimum operating condition,” said Marc Tremblay, president of Fluke Corporation. “This business will help us usher in the next generation of solutions for our industrial customers.” Fluke Corporation For information on Fluke tools and applications, or to find the location of your nearest distributor, contact Fluke Corporation, P.O. Box 9090, Everett, WA USA 98206, call (800) 44-FLUKE (800-443-5853), fax (425) 446-5116, e-mail firstname.lastname@example.org or visit the Fluke Web site at http://www.fluke.com. About Fluke Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measu
Janssen Seeks EMA Approval for Novel Subcutaneous Formulation of DARZALEX®▼ (daratumumab)19.7.2019 09:59:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of an extension application to the European Medicines Agency (EMA) for subcutaneous (under the skin) use of DARZALEX® (daratumumab) for the treatment of patients with multiple myeloma. This subcutaneous formulation of daratumumab is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20) [Halozyme's ENHANZE® drug delivery technology]. Daratumumab is currently only approved for intravenous (IV) use. “This new formulation is an example of our unwavering commitment to pursue innovative treatment options to support people living with multiple myeloma,” said Dr Patrick Laroche, Haematology Therapy Area Lead, Europe, Middle East and Africa (EMEA), Janssen-Cilag. “Importantly, subcutaneous daratumumab demonstrated comparable efficacy with the existing IV formulation, reduced the rate of infusion-related reactions and significantly shortened the time it takes for patients to receive treatment, fr